The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated×2•Originally published 7 May 2026•Updated 7 May 2026•

1 min read

Zealand Pharma Launches $200 Million Share Buy-back Program

Key Facts

1Zealand Pharma initiated a USD 200 million (DKK 1.3 billion) share buy-back program.

2The company maintains a robust cash position of USD 2.3 billion as of March 31, 2026.

28 days ago

Version History

Version 228 days ago

What changed: Added specific financial performance context regarding the smaller-than-expected operating loss for the first quarter.

Version 128 days ago

What changed: The story was updated to include Q1 2026 financial result details and development progress for the obesity assets petrelintide and survodutide.

Zealand Pharma has officially initiated a $200 million share buy-back program, supported by a robust cash position of $2.3 billion. In its Q1 2026 financial results, the company reported an operating loss that was smaller than analyst estimates, signaling better-than-expected fiscal management. During the quarter, the company also achieved significant development milestones for its key obesity drug candidates, petrelintide and survodutide. Liquidity is expected to be further bolstered by $700 million in milestone payments from Roche throughout 2026. This capital allocation strategy aims to return value to shareholders while maintaining aggressive investment in its metabolic health pipeline. Management's decision reflects strong confidence in future cash flows and the company's overall balance sheet stability.